Lilly Asia Ventures
VCs back $60m round for US, China-based Singlera Genomics
Chinese VCs Green Pine Capital Partners and Prosperico Ventures have led a $60 million Series A investment in US and China-based cancer diagnosis specialist Singlera Genomics.
AVCJ Awards: Fundraising of the Year - Venture Capital: Lilly Asia Ventures
Lilly Asia Ventures’ rapid-fire $450 million fundraise reflects increasing LP interest in the opportunities offered by the Chinese healthcare sector
Healthcare funds: Repeat prescription
An assortment of healthcare-focused GPs – most of them in China – have emerged to leverage rising domestic consumption and nascent medical innovation. Does domain expertise mean better deal access?
Deal focus: Just delivers on cross-border promise
Lilly Asia Ventures, Arch Ventures and Temasek have backed the expansion of Just Biotherapeutics' China-based manufacturing and research operation
Lilly Asia closes healthcare fund at $450m hard cap
China-focused Lilly Asia Ventures (LAV) has closed its fourth healthcare-focused fund at the hard cap of $450 million.
Temasek leads $57m round for China biotech firm
Singapore’s Temasek Holdings has led a $57 million Series B round for Chinese drug developer Hangzhou Just Biotherapeutics (Just China).
OrbiMed leads $19m round for Sino-US drug developer
OrbiMed Asia Partners has led a $19 million Series B round of funding for InventisBio, a pharmaceutical developer based in Shanghai with operations in China and the US.
VCs commit $65m to China vaccine developer CanSino Biologics
SDIC Fund Management, a GP under China’s State Development & Investment Corporation, has led a $65 million round of funding for CanSino Biologics, a China-based vaccine developer.
VIDEO: Judith Li, Lilly Asia Ventures
Judith Li, a partner with Lilly Asia Ventures, discusses healthcare investment opportunities in China